The company and all members of the board guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
Shenzhen Mousse Health Sleep Co., Ltd. (hereinafter referred to as "the Company") held its 17th meeting of the second board of directors on October 29, 2025, where it reviewed and approved the proposals on "Adjusting the Number of Directors and Amending the Articles of Association" and "Revising and Adding Certain Company Systems." Some sub-proposals of the proposal on adjusting the number of directors and amending the Articles of Association, as well as the proposal on revising and adding certain company systems, need to be submitted to the Company's fourth extraordinary shareholders' meeting in 2025 for review. The specific circumstances are announced as follows:
1. Main Situation Regarding Adjusting the Number of Directors and Amending the Articles of Association
To further enhance the Company's standardized operation level and improve the corporate governance structure, the Company intends to amend relevant provisions in the Articles of Association based on the latest regulations of the Company Law of the People's Republic of China (hereinafter referred to as "the Company Law"), the Guidelines for Articles of Association of Listed Companies, and the Shenzhen Stock Exchange Listing Rules (hereinafter referred to as "the Listing Rules"). The amendments to the Articles of Association will take effect after being approved by the Company's fourth extraordinary shareholders' meeting in 2025. From the effective date, the Company will no longer establish a supervisory committee, and the audit committee of the board of directors will exercise the relevant powers of the supervisory committee as stipulated in the Company Law. The "Rules of Procedure for the Supervisory Committee of Shenzhen Mousse Health Sleep Co., Ltd." will be abolished accordingly. Additionally, based on the proposed amendments to the Articles of Association and in conjunction with the Company's actual situation, the number of directors will be adjusted from 7 to 9, with the number of independent directors remaining at 3 and non-independent directors increasing from 4 to 6 (including one employee representative director). Furthermore, the personnel of the strategic committee, audit committee, nomination committee, and remuneration and assessment committee of the second board of directors will remain unchanged.